In Vivo Augmentation of Natural Killer Activity by Combined Treatment with Recombinant Gamma Interferon and Interleukin-2

Authors:
  • MSM. Refaat Shalaby
    M. Refaat Shalaby
  • LSLloyd P. Svedersky
    Lloyd P. Svedersky
  • PMPatrick A. Mckay
    Patrick A. Mckay
  • BFBryan S. Finkle
    Bryan S. Finkle
  • MPMichael A. Palladino
    Michael A. Palladino

Abstract
The in vivo regulation of natural killer (NK) cell function by recombinant murine gamma interferon (rMuIFN-gamma) and recombinant human interleukin-2 (rHuIL-2) was investigated. Peritoneal exudate-derived natural killer (PE-NK) cells of mice treated with rMuIFN-gamma or rHuIL-2 exhibited significantly enhanced cytolytic activities against YAC-1 target cells. Compared with animals receiving treatment with either rMuIFN-gamma or rHuIL-2 alone, the sequential treatment of mice with both agents resulted in a significantly greater enhancement of PE-NK cell function, especially when rMuIFN-gamma was administered 24 h before treatment with rHuIL-2. The cytolytic activities were significantly diminished after pretreatment of effector cells with anti-Qa-5 antiserum and complement but not with anti-Lyt-3.2 antiserum. These data constitute the first evidence demonstrating the association between IFN-gamma and IL-2 in the regulation of NK cell function in vivo, reinforce the potential benefit of combined treatment with biological response modifiers, and show that the schedule of administration may be a critical requirement for optimal benefits of combined lymphokine treatment in vivo.

This publication has 27 references indexed in Scilit: